| Mrs Shauna Elyse Hemingway, MD | |
|
169 Ashley Ave, Msc333, Charleston, SC 29425-8905 | |
| (843) 260-0212 | |
| Not Available |
| Full Name | Mrs Shauna Elyse Hemingway |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 10 Years |
| Location | 169 Ashley Ave, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215341078 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 37097 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Musc Health Florence Medical Center | Florence, SC | Hospital |
| Musc Medical Center | Charleston, SC | Hospital |
| Mcleod Regional Medical Center-pee Dee | Florence, SC | Hospital |
| Musc Health Marion Medical Center | Mullins, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Musc Community Physicians | 6507260668 | 698 |
News Archive
Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.
Cyanotech Corporation has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010.
"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.
One of the most common complications of sickle-cell disease occurs when deformed red blood cells clump together, blocking tiny blood vessels and causing severe pain and swelling in the affected body parts.
› Verified 7 days ago
| Entity Name | Carolina Family Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184655722 PECOS PAC ID: 4587557731 Enrollment ID: O20040203000627 |
News Archive
Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.
Cyanotech Corporation has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010.
"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.
One of the most common complications of sickle-cell disease occurs when deformed red blood cells clump together, blocking tiny blood vessels and causing severe pain and swelling in the affected body parts.
› Verified 7 days ago
| Entity Name | Carolinas Medical Alliance Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023238490 PECOS PAC ID: 9739096769 Enrollment ID: O20050201000341 |
News Archive
Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.
Cyanotech Corporation has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010.
"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.
One of the most common complications of sickle-cell disease occurs when deformed red blood cells clump together, blocking tiny blood vessels and causing severe pain and swelling in the affected body parts.
› Verified 7 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.
Cyanotech Corporation has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010.
"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.
One of the most common complications of sickle-cell disease occurs when deformed red blood cells clump together, blocking tiny blood vessels and causing severe pain and swelling in the affected body parts.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Shauna Elyse Hemingway, MD 169 Ashley Ave, Msc333, Charleston, SC 29425-8905 Ph: (843) 260-0212 | Mrs Shauna Elyse Hemingway, MD 169 Ashley Ave, Msc333, Charleston, SC 29425-8905 Ph: (843) 260-0212 |
News Archive
Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.
Cyanotech Corporation has been notified by the Nasdaq Listing Qualifications Panel that it is not in compliance with its continued listing requirements under Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) due to having only three independent directors of six total directors on its Board and fewer than three independent directors on its audit committee, while David I. Rosenthal serves as Interim President and CEO, as announced on March 1, 2010.
"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.
One of the most common complications of sickle-cell disease occurs when deformed red blood cells clump together, blocking tiny blood vessels and causing severe pain and swelling in the affected body parts.
› Verified 7 days ago
Bethany Anne Bruno, MD, MA Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-2300 | |
Matthew Kohler, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Ashlyn Holstein Savage, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Elsa C Caire, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2097 Henry Tecklenburg Dr, Suite 312w, Charleston, SC 29414 Phone: 843-769-5620 Fax: 843-769-5625 | |
Paula E Orr, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5319 Parkshire Way, Charleston, SC 29418 Phone: 843-767-2121 Fax: 843-767-2102 | |
Monica June Mitchum, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1027 Physicians Dr Ste 110, Charleston, SC 29414 Phone: 843-740-6700 Fax: 843-745-9428 | |
Phillip Andres Rodriguez, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 169 Ashley Ave, Room 202 Main Hospital Msc333, Charleston, SC 29425 Phone: 843-792-7108 |